Institutional investor Sagard Healthcare has closed a $250m (£196.6m) everlasting credit score facility with a syndicate of lenders.
The biopharmaceutical royalty and credit score investor hopes to develop the ability because it continues to increase its portfolio.
Because it was based in December 2019, Sagard Healthcare has invested greater than $1bn of capital by buying royalties in a spread of modern medication and offering biopharma firms with revolving credit score amenities.
Learn extra: Man Group plans to increase non-public credit score enterprise
“We consider that royalties are a horny asset class for traders, offering uncorrelated returns, inflation safety, and steady earnings technology,” stated David MacNaughtan, accomplice and head of Sagard Healthcare.
“Since inception simply 4 years in the past, the group has delivered on its funding aims and has constructed a diversified portfolio of those long-dated, cash-generating, biopharmaceutical royalties.
Learn extra: PGIM to take a position “important {dollars}” in non-public options
“The closing of our credit score facility, mixed with the primary shut of our subsequent fairness sequence, will permit us to constantly develop and diversify this asset base over time and ship engaging absolute and relative returns to our traders.”
The agency has additionally accomplished nearly $250m of latest royalty and credit score investments, together with an elevated funding in a credit score facility Phathom Prescribed drugs, and a one per cent royalty in Tyaso DPI web gross sales.
Learn extra: Personal credit score’s returns entice traders and asset managers alike